NCT03604198 2026-02-19Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing SyndromeCorcept TherapeuticsPhase 2 Active not recruiting125 enrolled
NCT07104812 2026-02-11Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)Mayo ClinicPhase 2 Recruiting15 enrolled
NCT06106295 2025-09-22Metyrapone for Mild Autonomous Cortisol Secretion (MACS)Mayo ClinicPhase 2 Active not recruiting30 enrolled
NCT07138274 2025-08-22Metyrapone Study for Patients Diagnosed With Mild Autonomous Cortisol Secretion - MACSMayo ClinicPhase 2 Not yet recruiting90 enrolled
NCT02468193 2020-05-06Study of Efficacy and Safety of Osilodrostat in Cushing's SyndromeNovartisPhase 2 Completed9 enrolled 22 charts
NCT02804750 2019-10-15Study to Evaluate CORT125134 in Participants With Cushing's SyndromeCorcept TherapeuticsPhase 2 Completed35 enrolled 13 charts
NCT00422201 2019-10-11Prospective, Open-Label, Multicenter, International Study of Mifepristone for Symptomatic Treatment of Cushing's Syndrome Caused by Ectopic Adrenal Corticotrophin Hormone (ACTH) SecretionHRA PharmaPhase 2 Terminated18 enrolled 9 charts
NCT02780882 2018-01-26SOM230 Ectopic ACTH-producing TumorsCedars-Sinai Medical CenterPhase 2 Withdrawn
NCT00958841 2016-07-26Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine OriginNovartisPhase 2 Terminated118 enrolled 11 charts